Skip to main content

Market Overview

Recap: Baudax Bio Q1 Earnings



Shares of Baudax Bio (NASDAQ:BXRX) remained unaffected after the company reported Q1 results.

Quarterly Results

Earnings per share rose 93.30% over the past year to ($0.27), which missed the estimate of ($0.19).

Revenue of $198,000 higher by 0.00% year over year, which missed the estimate of $630,000.

Looking Ahead

Baudax Bio hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: May 05, 2021

Time: 08:00 AM

ET Webcast URL:

Price Action

52-week high: $4.95

Company's 52-week low was at $0.97

Price action over last quarter: down 37.50%

Company Description

Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs, and a related proprietary chemical reversal agent and Dex-IN.


Related Articles (BXRX)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at